Crossmark

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants

Crossref DOI link: https://doi.org/10.1038/s41386-026-02428-9

Published Online: 2026-04-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Arikci, Denis

Borgulya, Joran

Straumann, Isabelle https://orcid.org/0009-0008-2952-586X
Vizeli, Patrick https://orcid.org/0000-0002-5954-4446
Luethi, Dino https://orcid.org/0000-0003-0874-4875
Thomann, Jan https://orcid.org/0000-0003-3820-2671
Rudin, Deborah https://orcid.org/0000-0003-3069-9732
Vukalovic, Ina

Eckert, Anne https://orcid.org/0000-0002-9341-3669
Liechti, Matthias E. https://orcid.org/0000-0002-1765-9659
Holze, Friederike https://orcid.org/0000-0003-3143-1519
Funding

Funding for this research was provided by:

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (32003B_185111)

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P5R5PM_225310)
License Information

Text and Data Mining valid from 2026-04-28

Version of Record valid from 2026-04-28
More Information

Article History

Received: 11 February 2026

Revised: 27 March 2026

Accepted: 17 April 2026

First Online: 28 April 2026

Competing interests

: MEL is a consultant for Definium Therapeutics Inc. and Resilient Pharmaceuticals. The other authors declare no conflicts of interests.

Document is current

Any future updates will be listed below